DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model

Recruiting

Conditions: Metastasis
Predictive Cancer Model

First Posted Date: 2024-01-11

Last Posted Date: 2024-02-09

Lead Sponsor: Fudan University

Target Recruit Count: 166

Registration Number: NCT06202404

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab paclitaxel

First Posted Date: 2024-01-09

Last Posted Date: 2024-03-21

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06196788

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: H101
Drug: Camrelizumab

First Posted Date: 2024-01-09

Last Posted Date: 2024-03-26

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT06196671

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4

Recruiting

Conditions: Advanced Thyroid Cancer Patients Who Received Target Therapy

Interventions: Drug: dabrafenib plus trametinib with or without PD-1 antibody
Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Drug: anlotinib or anlotinib plus anti-PD-1 antibody
Drug: lenvatinib plus anti-PD-1 antibody

First Posted Date: 2024-01-08

Last Posted Date: 2024-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT06195228

Locations: 🇨🇳
Shanxi Cancer Hospital, Shanxi, Taiyuan, China
🇨🇳
Caixia Liu, Hohhot, Inner Mongolia, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Phase 3

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma
Oligometastatic Disease
Radiotherapy

Interventions: Combination Product: PD-1 inhibitor+/- chemotherapy combined with local therapy
Drug: systemic therapy alone

First Posted Date: 2024-01-05

Last Posted Date: 2024-05-02

Lead Sponsor: Fudan University

Target Recruit Count: 354

Registration Number: NCT06190782

Locations: 🇨🇳
Fudan University Shanghai cancer center, Shanghai, China

Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Radiation: thoracic radiotherapy

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-09

Lead Sponsor: Fudan University

Target Recruit Count: 28

Registration Number: NCT06187740

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: HER-2 Protein Overexpression
Non-muscle Invasive Bladder Cancer

Interventions: Drug: Disitamab vedotin
Drug: Bacillus Calmette Guerin Vaccine

First Posted Date: 2024-01-02

Last Posted Date: 2024-07-12

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06187506

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

Phase 1

Recruiting

Conditions: Renal Cell Carcinoma

Interventions: Combination Product: Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells

First Posted Date: 2023-12-27

Last Posted Date: 2023-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 9

Registration Number: NCT06182735

Locations: 🇨🇳
Jian Zhang, Shanghai, China

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Tislelizumab combined with GX
Drug: Tislelizumab combined with GP

First Posted Date: 2023-12-20

Last Posted Date: 2024-01-17

Lead Sponsor: Fudan University

Target Recruit Count: 266

Registration Number: NCT06177301

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

Not Applicable

Not yet recruiting

Conditions: Colorectal Neoplasms

Interventions: Combination Product: DEBIRI Combined With Chemotherapy and Bevacizumab

First Posted Date: 2023-12-20

Last Posted Date: 2023-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 39

Registration Number: NCT06177288

Locations: 🇨🇳
Zhongshan hospital, Fudan university, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy